Principal Securities, Inc. Iovance Biotherapeutics, Inc. Transaction History
Principal Securities, Inc.
- $3.63 Trillion
- Q2 2024
A detailed history of Principal Securities, Inc. transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Principal Securities, Inc. holds 127 shares of IOVA stock, worth $1,271. This represents 0.0% of its overall portfolio holdings.
Number of Shares
127
Previous 139
8.63%
Holding current value
$1,271
Previous $2.06 Million
50.53%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding IOVA
# of Institutions
323Shares Held
239MCall Options Held
1.27MPut Options Held
1.68M-
Vanguard Group Inc Valley Forge, PA26MShares$260 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY25.9MShares$260 Million6.02% of portfolio
-
Mhr Fund Management LLC New York, NY24MShares$240 Million28.39% of portfolio
-
Black Rock Inc. New York, NY21.2MShares$212 Million0.0% of portfolio
-
State Street Corp Boston, MA12.6MShares$126 Million0.0% of portfolio
About IOVANCE BIOTHERAPEUTICS, INC.
- Ticker IOVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 157,800,992
- Market Cap $1.58B
- Description
- Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...